ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.
Also called NCT02319005
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 206 participants
- Sponsor
- Registry
-
NCT02319005
-
- Other papers using this trial's data
- Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, France, Germany, Italy, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02319005. Randomized; double masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2017-03-30 (actual). Results posted on 2018-07-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
- Condition
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
- Condition
- Amyloidosis, Hereditary
- Condition
- Amyloid Neuropathies, Familial
- Condition
- Amyloid Neuropathies
- Condition
- Amyloidosis, Hereditary, Transthyretin-Related
- Condition
- Familial Transthyretin Cardiac Amyloidosis
- Intervention (Drug)
- Revusiran (ALN-TTRSC)
- Intervention (Drug)
- Sterile Normal Saline (0.9% NaCl)
- Lead sponsor
- Alnylam Pharmaceuticals
Record details
- Record id
cardio:ct-nct02319005- Content hash
83c8abb176d361e216c3cfa906f75f1ba42776fed44bfe6ee30f244f22417f44